stockrowProtagonist Therapeutics, Inc.
PTGX Healthcare Biotechnology
Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024.
- Revenue
- +3,749.2%
- EPS
- +549.1%
- Free cash flow
- +839.7%
Quarter to June 2026, against a year earlier
Follow PTGX
Alert me
Protagonist Therapeutics, Inc. (PTGX) Revenue growth
Protagonist Therapeutics, Inc.'s revenue growth over the twelve months to 30 June 2026 was 34.8%, up 124.2 percentage points from fiscal 2025 (−89.4%). Over the past ten years it has ranged from −99.3% (fiscal 2019) to 12,293.1% (fiscal 2020); the current reading is higher than 22% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | −89.4% | (713.47) |
| FY2024 | 624.1% | 498.33 |
| FY2023 | 125.7% | 128.57 |
| FY2022 | −2.84% | 1.60 |
| FY2021 | −4.44% | (12,297.51) |
| FY2020 | 12,293.1% | 12,392.32 |
| FY2019 | −99.3% | (153.39) |
| FY2018 | 54.1% | 89.26 |
| FY2017 | −35.1% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 3,749.2% | 3,650.14 |
| Mar 2026 | 99.0% | 194.67 |
| Dec 2025 | −95.6% | (96.43) |
| Sep 2025 | 0.79% | (32.30) |
| 26 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| IBRX ImmunityBio, Inc. compare | 192.9% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 92.8% |
| TGTX TG Therapeutics, Inc. compare | 76.1% |
| CAI Caris Life Sciences,�Inc. compare | 68.8% |
| PTGX Protagonist Therapeutics, Inc. | 34.8% |
| CYTK Cytokinetics, Incorporated compare | 29.9% |
| KRYS Krystal Biotech, Inc. compare | 26.0% |
| TWST Twist Bioscience Corporation compare | 19.2% |
| SYRE Spyre Therapeutics, Inc. compare | −81.8% |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on PTGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement